Full Press Release Details
Incorporated (ISRY.OB)
at the Roth Capital Partners New York Conference Call
Speaker, IsoRay Incorporated>>
we ready to go? Thank you all for coming to this conference. I appreciate being
here. I would like to have you make sure you look at this forward-looking
statement, read it carefully and it's fully listed on our website. So please
forward and look at that.
all, I would like to tell you a title bit about IsoRay. IsoRay
it's an isotope company, which focuses on innovative brachytherapy solutions
prostrate and other malignant tissue through the use of our proprietary
Cesium-131. The merits of IsoRay are many, but we all are faced with the
possibility of someday having help of having cancer or getting cancer. So
consequently this isotope Cesium-131 is the first new isotope to hit the market
segment, the brachytherapy market segment in over 20 years.
very large market. In the United States is about $4 billion market now and
obviously prostrate cancer, the baby boomers are just now coming of age and
the market is growing rapidly. We also -- it's very unique in fact that Cesium,
when we got our FDA approval to market, we got FDA approval to market to all
soft tissue malignant tumors in the body and that includes the brain, the
pancreas, the liver, lung and breast. So it's a very large opportunity that
the unique things about the Company is that, we started our marketing campaign
into the actual market by picking a number of the largest sites in the United
States and we have currently approximately 54 of the major oncology centers
the United States, over the last 22 months, have adopted and are using or we'll
soon be using Cesium-131.
the reasons for this adoption is that Cesium offers some real unique advances
the market. It is an isotope that has a very short half-life. It's a gamma
it has a very high energy. The other thing is that we have -- over the years,
have patented -- all of our technology is patented and we have been able to
create a commercialization of this isotope, which up to now has been very
there is expected to be somewhere around 30,000 deaths just in the United States
alone from prostrate cancer. It's our second leading cause of death in men and
it will be increasing overtime obviously as the population of men over, say,
50 continues to increase.
there was about 230,000 new cases diagnosed in the United States and one of
unique things about prostrate cancer is if you get diagnosed, the death rate
should fall because currently only about 53% of all men over the age 50 are
regularly screened for prostrate cancer. And as these baby boomers hit the
market, and that includes I think all of us, the market is really under a siege
in how to take care of this disease.
chart here which shows kind of the breakout of the treatment options, the
different treatment options for prostrate cancer. There are like - I said
earlier there are about 230,000 new cases a year, of those about a 103,000
approximately are treated with what we would now call brachytherapy. And in
brachytherapy category, as you can see there are many different uses such as
happens is that, we in the brachytherapy side are experiencing a growth that's
unprecedented in this market over the last few years. And one of the primary
reasons for that is, is that the radiographs, or our ability to identify, where
we put the radioactive seeds, if you will, has been greatly enhanced with the
furthering of all the new imaging. And going forward, we're going to even have
some greater opportunity with the new markers that are coming on in the market,
and that will again allow us to be more specific with our brachytherapy
see here from this particular chart that brachytherapy, using the seeds has
distinct advantage over a lot of the other procedures. Let me give you a
specific example. If you're going to use external beam IMRT trial or others,
often have long duration. For example, with IMRT, you're going to be up to
weeks being treated. And that creates a very disruptive lifestyle, as you try
take care of your cancer whereas with the brachytherapy with the seed, as you
can see is basically one 30 to 45 minute procedure, that's an outpatient
procedure, no hospitalization.
basically go home that afternoon. And the next day in most cases you are at
or playing golf or whatever you're doing. So it is really a distinct advantage,
it also has to its credit a lot less toxicity, than a lot of the other
opportunities you have to treat the cancer. So it is a high energy isotope
has a very short half-life and the toxicity and the modalities are considerably
less then with other modalities.
can see on this chart that, this is really telling this is talk about treatment
you can see in the blue on the right that's the brachytherapy seeds. On the
first chart on the left you can see the cost factor. Our average cost for the
entire operation is somewhere between $13,000 and $17,000 for the entire cost
for the outpatients stay and all of the different procedures that you do pre
post, versus some of the other procedures you can see are much more expensive.
might add that one of our one of the old or older is radical prostatectomy
with radical prostatectomy it competes with brachytherapy. But as brachytherapy
becomes more specific and more exact, radical prostatectomy is beginning to
in the lines, I believe in 2004 there were more brachytherapy procedures than
there were radical prostatectomy.
graph, certainly shows why, in the second graph you can see the treatment and
the recovery days. And you can see where the one or two days on brachytherapy
a dramatic influence on choices and thus does the heighten demand for
brachytherapy. There are also some other life issues, which are critical, I
think to all of us and that's the incontinence and the impotence. And that
something the quality of life, which we all have to consider. But this new
isotope, it really approaches and as we, I believe now are over 500 patients
implants and we're finding the results of this to follow this graph you have
graph shows the growth of the brachytherapy seed market. And because of the
quality of life and the less toxicity, you can see that there has been a pretty
steady growth, through the 90s and then up into current, and we can -- we would
expect the growth to actually increase as a percentage of all cases diagnosed.
One of the markets -- one of the barriers that we've had is that prior to the
late 1998, '99, 2000 that area, imaging was very difficult. And often times
couldn't image the seeds, so they couldn't place them in or around the tumor
the kind of preciseness that they needed. But as imaging got better the results
got dramatically better.
slide that shows for those of you who are not familiar, this shows the prostate
lays in next to the bladder and is in a very sensitive area, obviously. And
shows the -- the diagram here shows that as you place the seeds and as you
the three dimension picture of it, the seeds can be place very exact in and
is just an educational slide for you, so you can see that.
the advantages of Cesium over its competitors, is that it has a uniform